BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191118
DTEND;VALUE=DATE:20191121
DTSTAMP:20260515T052243
CREATED:20180531T073809Z
LAST-MODIFIED:20190605T115541Z
UID:16039-1574035200-1574294399@www.pharmajournalist.com
SUMMARY:Ophthalmic Drugs
DESCRIPTION:SMi Group are pleased to present the 3rd Annual Ophthalmic Drugs Conference and Focus Day\, taking place on the 18th-20th November 2019 in London\, UK. \n \nThe global ophthalmic drug market size is expected to reach a value of $30 billion USD by 2023 with growing focus on alternative delivery approaches to replace intravitreal drug delivery and novel drug development being the key factors driving the market. \nWith this in mind\, this year’s Ophthalmic Drugs conference will explore new discoveries in the treatment of ocular rare disease; innovations in gene therapy; the challenges in drug delivery through a complex barrier; patient comfort and regulatory compliance which make up  core components within the Ophthalmic Drug sphere. \nNEW FOR 2019: \nThe brand-new Focus Day on ‘Novel Drug Delivery Through a Complex Barrier’ will bring academic perspectives on the future for ocular drug delivery and notified bodies will provide a regulatory insight into this emerging field of ophthalmic drug development. \nHow will you benefit? \nWith over 15 expert presentations\, the three-day agenda offers you peer-to-peer networking with Global Product Managers\, Heads of Drug Development\, Senior Directors of Ophthalmology\, Heads of Research and Development and many more! \nNetwork and learn from leading professionals such as: \nCHAIRS FOR 2019: \n\nMitchell de Long\, Vice President\, Chemistry\, Aerie Pharmaceuticals\nNaj Sharif\, Vice President\, Global Ophthalmology\, Santen Inc\, USA\n\nFEATURED SPEAKERS INCLUDE: \n\nParisa Zamiri\, Global Head of Clinical Development in Ophthalmology\, Novartis Pharmaceutical Inc.\nGavin Spencer\, Executive Vice President and Chief Business Officer\, Nicox\nAniz Girach\, Chief Medical Officer\, ProQR Therapeutics\nDaniel Chung\, Global Medical Strategy Lead- Ophthalmology\, Spark Therapeutics\nMichael Ehrlich\, Senior Clinical Program Lead – Retinopathies\, Boehringer Ingelheim\nPeter Morgan-Warren\, Medical Assessor\, MHRA\nWilliam Dallman\, Clinical Development Manager\, Eyenuk\n\nFor more information and to register\, visit: www.ophthalmicdrugs.com/pj \nEarly-Bird Rates \n\nBOOK BY 28TH JUNE AND SAVE £300\nBOOK BY 30TH SEPTEMBER AND SAVE £100\n\nSocial Media Handles \nFollow us on LinkedIn ‘SMi Pharma’\, Twitter @SMiPharm and use #OphthalmicDrugs \nContact Info: \nT: +44 (0) 20 7827 6164\nE: nhoward@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/ophthalmic-drugs-2019/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:nhoward@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191118
DTEND;VALUE=DATE:20191121
DTSTAMP:20260515T052243
CREATED:20180905T081807Z
LAST-MODIFIED:20190717T092148Z
UID:17493-1574035200-1574294399@www.pharmajournalist.com
SUMMARY:3rd Annual Anti-Fibrotic Drug Development Summit (AFDD) 2019
DESCRIPTION:AFDD is back for its third year as the only conference to bring together industry leaders\, clinicians and academic experts focused on finding an effective anti-fibrotic treatment. \n \nOver 3 days packed with compelling case studies\, diverse panels and varied networking opportunities\, you’ll glean insights from industry and academic leaders across fibrotic disease areas. The 2019 agenda will reflect the strides taken by the community over the past year as well as forming the future of anti-fibrotic drug development. \nTo learn more about this event\, and to register online\, visit https://afdd-summit.com/ \nContact:\nPhone – (+1) 617 455 4188\nEmail – info@hansonwade.com
URL:https://www.pharmajournalist.com/event/afdd-summit-2019/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191119
DTEND;VALUE=DATE:20191121
DTSTAMP:20260515T052243
CREATED:20190809T095122Z
LAST-MODIFIED:20190813T105926Z
UID:21871-1574121600-1574294399@www.pharmajournalist.com
SUMMARY:1st RNA Editing Summit 2019
DESCRIPTION:  \nTranslating Emerging RNA Editing Approaches for Therapeutic Applications. \nAs CRISPR genome editing struggles to overcome key specificity and delivery challenges in its pursuit to realize therapeutic applications\, the 1st RNA Editing Summit 2019 accelerates the translation and commercialization of RNA editing for an array of research and therapeutic applications. \nAs the therapeutic potential of RNA editing explodes\, discover the fundamental mechanisms of RNA editing\, such as recruiting endogenous ADARs with encodable guideRNAs\, and learn about the novel approaches being developed to precisely and efficiently deliver intended RNA edits. With the temporary nature of RNA editing providing a huge opportunity in many areas beyond genetic diseases\, uncover how to recruit endogenous editing enzymes and ultimately deliver safe and effective transcriptome edits. \nJoin RNA\, functional genomic\, cell biology and immuno-oncology experts from large pharma\, biotech and academia at the 1st RNA Editing Summit 2019 in the pursuit of translating emerging RNA editing mechanisms into therapeutic reality. \nTo learn more about this event\, and to register online\, visit https://ter.li/jikni6
URL:https://www.pharmajournalist.com/event/1st-rna-editing-summit-2019/
LOCATION:Revere Hotel Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191119
DTEND;VALUE=DATE:20191122
DTSTAMP:20260515T052243
CREATED:20190910T085210Z
LAST-MODIFIED:20190910T085210Z
UID:22357-1574121600-1574380799@www.pharmajournalist.com
SUMMARY:3rd Annual Dermatology Drug Development Summit
DESCRIPTION:The Dermatology Drug Development Summit series is a unique industry-focused forum dedicated to innovating\, accelerating and sharing pharmaceutical best practice on the development and bringing to market of new dermatological drugs\, in the treatment of high unmet need. \nThe 3rd Annual Dermatology Drug Development Summit provides leading industry experts with a unique forum to debate the end-to-end challenges in dermatology drug development: from discovering new research on key disease pathways\, to unveiling critical preclinical insights\, discussing formulation strategies\, defining the optimal clinical development plans or evaluating commercialization approaches. \nJoin peers and leaders in this space for an exclusive three-day meeting of comprehensive discussion\, sharing of latest advances and pioneering insights\, and networking opportunities. \nHear from 30+ experts including: \n\nSonya Abraham\, Head of New Treatment Strategies\, Immunology\, UCB\nDavid Rubenstein\, CSO\, Dermavant Sciences\nKendall Marcus\, Director – Division of Dermatology & Dental Products\, FDA\nMichael Kuligowski\, Executive Medical Director – Inflammation & Autoimmunity\, Incyte Corporation\nJohn Harris\, Vice Chair of Dermatology & Director\, Vitiligo Clinic & research Center\, University of Massachusetts Medical School\nSuma Krishnan\, Founder & COO\, Krystal Biotech\n\nAcross an end-to-end\, comprehensive agenda\, learn from case studies on: \n\nHow to enhance preclinical activities\nThe latest advances in translational research\nHow to advance topical drug development and formulation approaches\nHow to accelerate clinical development and what are the latest clinical results\nHow to tackle the evolving regulatory and commercial landscape in dermatology\n\nFind out more here: https://ter.li/jj7wxg
URL:https://www.pharmajournalist.com/event/3rd-annual-dermatology-drug-development-summit/
LOCATION:Aloft Boston Seaport District\, Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191119
DTEND;VALUE=DATE:20191122
DTSTAMP:20260515T052243
CREATED:20190924T113636Z
LAST-MODIFIED:20190924T113636Z
UID:22548-1574121600-1574380799@www.pharmajournalist.com
SUMMARY:Gene Therapy Analytical Development
DESCRIPTION:The inaugural Gene Therapy Analytical Development Summit will unite large pharma and innovative biotechs to develop robust analytical tools to guarantee the consistency\, quality and safety of gene therapy products. \n \nFocused specifically on addressing the unique analytical challenges posed by gene therapy vectors\, this technical scientific meeting will unite the ‘boots on the ground’ scientists grappling with these challenges first-hand. \nDelving into technical analytics to assess potency\, capsid integrity\, empty vs full capsids and viral titers of AAV and lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development. \nTo learn more and to register online\, visit https://ter.li/z1fc6v
URL:https://www.pharmajournalist.com/event/gene-therapy-analytical-development/
LOCATION:Renaissance Boston Waterfront Hotel 606 Congress Street Boston\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191126
DTEND;VALUE=DATE:20191128
DTSTAMP:20260515T052243
CREATED:20190918T074903Z
LAST-MODIFIED:20190918T094740Z
UID:22454-1574726400-1574899199@www.pharmajournalist.com
SUMMARY:Targeting RNA Congress
DESCRIPTION:Targeting RNA Congress\n \nNearly 100% of all small molecule drugs in the market are designed to target proteins. However\, only 2% of the human genome actually codes for proteins\, leaving the remaining noncoding DNA and in turn RNA as potentially untapped therapeutic targets. \n \nTo date\, industry has focused on biological products for RNA therapeutics but the emergence of epitranscriptomics and bioinformatics tools has provided the field with a new range of drug modalities. This has led to increasing capital investment alongside collaborations within pharma and biotech to assess if RNA can be a drug target. \nThe Targeting RNA Congress will explore the ‘undruggable’ RNA space and showcases the latest advancements in modulation of RNA directly with small molecules and through epigenetics. The meeting will bring together academic and industry leaders who are building platforms to identify and validate targets in order to assess disease relevance approaches in the RNA world. You’ll take away actionable insights including: \n\n Strategies to go from hit-to-lead candidates\n Addressing structural biology\, biochemical and biophysical attributes relevant for RNA\n Approaches to overcome chemical hurdles associated with new drug discovery platforms\n How mapping RNA upstream regulation can develop disease prevention products\n\n“This meeting is an excellent opportunity to interact with one of the best collections of thought leaders and drug discovery experts in the field of epitranscriptomics\, and I am looking forward to exchanging strategic insights with my colleagues aiming at unlocking an entire class of previously undruggable targets” – Dr. Gerhard Mueller\, Chief Scientific Officer\, Gotham Therapeutics \nTo learn more about Targeting RNA Congress and to register online\, visit: https://go.kisacoresearch.com/l/678123/2019-09-16/ldwx
URL:https://www.pharmajournalist.com/event/targeting-rna-congress/
LOCATION:TBC
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191202
DTEND;VALUE=DATE:20191205
DTSTAMP:20260515T052243
CREATED:20190815T095332Z
LAST-MODIFIED:20190815T095403Z
UID:21972-1575244800-1575503999@www.pharmajournalist.com
SUMMARY:2nd Annual RNA Targeted Drug Discovery
DESCRIPTION:At a time when the previously untapped drug discovery opportunity promised within RNA opens up\, the 2nd RNA- Targeted Drug Discovery Summit returns to reunite the leading minds from large pharma\, innovative biotech and KOLs of academia to discuss unique discovery and development challenges that must be overcome for novel RNA targeted small molecule therapeutics to achieve their seemingly limitless potential. \n \nFor the 2nd year\, network with the KOLs and RNA pioneers\, to gain a comprehensive understanding on how to translate the first generation of RNA targeted small molecules into the clinic\, stimulate the discussion of successfully targeting RNA via interfering with RNA-protein interactions and seize the therapeutic opportunity in hand by re-defining the undruggable nature of RNA. \nDownload the Full Event Guide. \nWith 22 world-class speakers sharing their latest findings\, join those who are re-defining the undruggable nature of RNA: \n\nKevin Weeks\, Founder of Ribometrix; Professor of Chemistrym\, University of North Carolina\nFrank Slack\, Co-Founder of Twentyeight-Seven Therapeutics; Professor\, BIDMC\nKathryn McCabe\, Sr. Director of Business Development\, Eli Lilly\nMartin Pettersson\, Research Fellow\, Pfizer\nChristopher Barbieri\, Senior Investigator\, Bristol-Myers Squibb\nJennifer Petter\, Founder & CSO\, Arrakis Therapeutics\nYochi Slonim\, Co-founder & CEO\, Anima Biotech\nGerhard Mueller\, CSO\, Gotham Therapeutics\nChristopher R. Trotta\, VP\, Biology\, PTC Therapeutics\n\nThis is only some of the senior experts confirmed to present – check out the full speaker faculty and case studies here. \nOnce again join your RNA community at this translational and industry dedicated event focused on optimizing target validation\, improving drug-like properties & accelerating the translation of selective and bioactive RNA targeted small molecule therapeutics into human clinical trials. \nCheck out the official event guide for full speaker details or if you’re ready to register\, secure your place here.
URL:https://www.pharmajournalist.com/event/2nd-annual-rna-targeted-drug-discovery/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191203
DTEND;VALUE=DATE:20191206
DTSTAMP:20260515T052243
CREATED:20190909T090526Z
LAST-MODIFIED:20190909T101000Z
UID:22341-1575331200-1575590399@www.pharmajournalist.com
SUMMARY:Oncolytic Virotherapy Summit 2019
DESCRIPTION:Now in its 5th year\, the Oncolytic Virotherapy Summit is the industry’s definitive guide to turning viral vehicles into clinically effective therapeutics across oncology indications. With 3 days of in-depth cutting-edge case studies and the highest calibre of industry discussions\, The OV Summit will provide the roadmap to oncolytic virotherapy success. \nHear from pharma and biotech companies of all sizes\, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities. Discover the development of oncolytic viruses that engage the immune system for long-term treatment and management of cancers. \nTo learn more and to register online\, visit: http://bit.ly/2kmZGQh
URL:https://www.pharmajournalist.com/event/oncolytic-virotherapy-summit-2019/
LOCATION:Westin Boston Waterfront\, 425 Summer St\, Boston\, MA 02210
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191203
DTEND;VALUE=DATE:20191206
DTSTAMP:20260515T052243
CREATED:20191101T093844Z
LAST-MODIFIED:20191101T093844Z
UID:23150-1575331200-1575590399@www.pharmajournalist.com
SUMMARY:3rd Microbiome Movement – Gut-Brain Axis Summit
DESCRIPTION:The 3rd Microbiome Movement – Gut-Brain Axis Summit is returning to Boston this December and will unite pioneering industry and academic researchers to establish the mechanistic pathways contributing to neurological disorder manifestation\, overcome the scientific and translational challenges of working in the gut-brain setting and capitalize on this therapeutic opportunity. \n \nThis meeting provides the opportunity for you to: \n\nDiscover pioneering preclinical data implicating metabolic\, immune-mediated and enteroendocrine pathways in CNS disease development\nExplore translational approaches that are moving microbiome gut-brain axis science from association to causation\nLearn about critical considerations for microbiome clinical trials in the neurological and mental health setting to inform symptom and treatment management\nRealize the potential of microbial profiles as a biomarker for patient stratification to maximize the efficacy of already existing drugs for neurological disease\nUncover the relatively untapped commercial opportunity held by nutritional and therapeutic products for neurological and mental health\n\nThere is no question that the early market activity in the microbiome gut-brain axis space is critical in shaping its success. Join us to discover the microbiome science contributing to neurological disease and develop the next generation of microbiome-targeted products for improved neurological and mental health outcomes. \nFind out more here: https://ter.li/t9gsy7
URL:https://www.pharmajournalist.com/event/3rd-microbiome-movement-gut-brain-axis-summit/
LOCATION:Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:katie.jacobs@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191204
DTEND;VALUE=DATE:20191206
DTSTAMP:20260515T052243
CREATED:20190410T071442Z
LAST-MODIFIED:20191008T060245Z
UID:20275-1575417600-1575590399@www.pharmajournalist.com
SUMMARY:HR Life Sciences
DESCRIPTION:With the rapid rise of digital technology and shifts within the larger healthcare industry\, the need to find new talent that can drive innovation has never been more critical. HR Life Sciences is specifically designed for senior HR professionals at the nation’s leading Pharmaceutical\, Biotech and Medical Device companies. You’ll discover the tools\, insights\, innovations\, and cutting-edge solutions needed to evolve your hiring strategies in a rapidly changing life science industry. Register now with code PHARMAJ20 and receive a 20% discount. \n \nAt HR Life Sciences\, you’ll learn how to: \n\nRefine your talent sourcing to meet shrinking\, highly competitive talent pools\nRetain and develop top talent in an ever-changing market full of mergers & acquisitions\nKeep up with new and emerging employee engagement & development trends\nStay ahead of the curve with new HR technologies and tools suited to your workforce\nMaintain HR’s position as a visible business partner & thought-leader
URL:https://www.pharmajournalist.com/event/hr-life-sciences/
LOCATION:San Diego\, CA
ORGANIZER;CN="Worldwide Business Research":MAILTO:hrlifesciences@wbresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191204
DTEND;VALUE=DATE:20191207
DTSTAMP:20260515T052243
CREATED:20190930T095204Z
LAST-MODIFIED:20190930T104919Z
UID:22646-1575417600-1575676799@www.pharmajournalist.com
SUMMARY:8th annual PREDiCT: Tumour Models London
DESCRIPTION:The 8th annual PREDiCT: Tumour Models London Summit will return this December with a new speaker faculty to help you benchmark your oncology model selection strategy and target validation. With the rise of immuno-oncology\, model requirements\, target validation and the importance of tumour micro-environment are key to clinical success. The 3-days summit will provide you with real world data from a selected model experts\, including Merck\, MedImmune\, Takeda\, Roche\, AstraZeneca and more for practical insights. \nTo learn more about 8th annual PREDiCT: Tumour Models London and to register online\, visit https://ter.li/6ge5rc
URL:https://www.pharmajournalist.com/event/8th-annual-predict-tumour-models-london/
LOCATION:London\, UK\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191205
DTEND;VALUE=DATE:20191207
DTSTAMP:20260515T052243
CREATED:20190531T111302Z
LAST-MODIFIED:20190614T081716Z
UID:21011-1575504000-1575676799@www.pharmajournalist.com
SUMMARY:SMi’s Inaugural Conference: Respiratory Drug Delivery 2019
DESCRIPTION:SMi are pleased to announce the launch of the Respiratory Drug Delivery conference as part of the newly branded Asthma and COPD series\, which will be held in London on the 5th – 6th December 2019. \n \nWith the rising prevalence of respiratory disease such as Asthma\, cystic fibrosis and COPD\, this group of diseases are now amongst the leading cause of death\, affecting over 500 million adults and children worldwide. Lung cancer now accounts for over 50% of all respiratory disease related deaths in Europe\, yet little work is being done to reduce this high mortality rate. \nOpportunities for drug development has effectively resulted in the global pulmonary and respiratory drug delivery market expecting to reach 64 billion USD (6.7% CAGR) by 2025. However\, the unmet medical needs of respiratory diseases sufferers remain. \nJoin us this year as SMi aim to bring together clinical researchers\, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments that adhere to patient’s needs\, analysing the success of digital media devices and connective health technology in aiding the diagnosis of severe asthma and COPD. This year will also investigate the developing issues surrounding pulmonary and nasal combination product design. \nBenefits of attending: \n\nAssessing how to transform disease management through drug combinations\, devices and inhaled biological treatments\nEvaluating respiratory device design development and novel technologies such as nanoparticle-based drug delivery\nExploring digital connective inhalation to improve patient centricity\nReviewing the challenges around the pricing and reimbursement of respiratory drug products\n\nView the full agenda online: www.respiratorydrugdelivery.com/pharmajwl \nEarly bird rates: \n\nBOOK BY 28TH JUNE AND SAVE £300\nBOOK BY 30TH SEPTEMBER AND SAVE £100\n\nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #SMirespiratory\nLinkedIn: follow our company page – search ‘SMi Pharma’ \nContact \n+44 (0) 20 7827 6088\nhsidhu@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/respiratory-drug-delivery-2019/
LOCATION:Holiday Inn Kensington Forum\, 97 Cromwell Road\, London\, SW7 4DN\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191210
DTEND;VALUE=DATE:20191212
DTSTAMP:20260515T052243
CREATED:20190909T102201Z
LAST-MODIFIED:20190909T123702Z
UID:22345-1575936000-1576108799@www.pharmajournalist.com
SUMMARY:BioFIT 2019
DESCRIPTION:EARLY-STAGE INNOVATIONS | ACADEMIA-INDUSTRY COLLABORATIONS | TECHNOLOGY TRANSFER | SEED INVESTMENT \nWith the highest attending rate of TTOs\, research institutes and academia together with big pharma\, emerging and small biotech\, diagnostics companies\, pre-seed / seed / Series A investors\, BioFIT is the leading partnering event in Europe for technology transfer\, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed\, seed and Series A investment in Life Sciences. \nWHY ATTEND BIOFIT? \nOut of 1\,000 BioFIT attendees\, 1\,000 deals have been generated. The breakdown in terms of nature of deals is the following: \n\n35% of collaborative research projects\n30% of licensing deals\n15% of equity investment deals\n20% of services deals\n\nEstimate based on the measurement of 2015 and 2016 delegates’ outcomes \n  \nKEY FIGURES: \n\n1\,300+ delegates\n800+ organisations\n35+ countries represented\n1\,000 deals generated in 2017\n\nINSIDE THE EVENT: \n\nA business convention with pre-qualified one-to-one meetings\n Identification of would-be CEOs\nConferences and roundtable discussions\nOral presentations of start-ups \, licensing opportunities stemming from academia \, service presentations\nAn exhibition area\nInformal networking evenings\n\nPlease check out the different participants’ lists of the previous editions\, as well as the list of this year’s edition >>here<<.\n2018 Final programme\n2019 Preliminary programme \nPlease feel free to widely share this document with your colleagues\, network\, partners… \nBE PART OF THE EVENT: \n\nRegister now\nBook your booth now\n\nWebsite: www.biofit-event.com\nTwitter: @BIOFIT_EVENT
URL:https://www.pharmajournalist.com/event/biofit-2019/
LOCATION:MARSEILLE CHANOT\, PALAIS DES CONGRÈS ET DES EXPOSITIONS Rond Point du Prado 13008 Marseille – FRANCE
ORGANIZER;CN="Eurasant%C3%A9":MAILTO:msatola@eurasante.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191210
DTEND;VALUE=DATE:20191213
DTSTAMP:20260515T052243
CREATED:20191101T123339Z
LAST-MODIFIED:20191101T124951Z
UID:23209-1575936000-1576195199@www.pharmajournalist.com
SUMMARY:Cell Therapy Analytical Development Summit
DESCRIPTION:The explosion in cell therapy development companies has fueled a need to develop well-characterized clinical products which has resulted in the call for robust and validated analytical assays now being louder and more important than ever before. \nThe inaugural Cell Therapy Analytical Development Summit brings you the leaders in CMC\, analytics and process development to create standardized and automated analytical techniques and technologies for improved therapeutic characterization at scale. \nJoin over 100 of the world’s experts as we discuss how to navigate a murky regulatory landscape\, robustly validate assays and advance the characterization of CAR-T and TCR cell therapy analytics to ensure safe\, consistent and quality cell therapy products. \n \nGet involved this December to: \n\nAddress the need to fully understand the mechanism of action of a cell therapy to develop representative potency assays\nAssess methods to develop functional assays suitable for routine and timely testing to overcome operational constraints\nExplore ways to develop non-destructive and non-invasive in-line analytics\nDiscuss current techniques being developed to standardize flow cytometry and explores ways to overcome batch effects\nHighlight sources of variability in cell counting measurement such as environmental\, procedural\, analytical and instrumental\, and techniques to minimize variability\n\nWhy do experts attend our cell therapy summits? \n“Moments where we can come together with passionate individuals and companies who are focused on advancing cancer care are inspiring\, and the Cell Therapy Summit is no different. We are energized by the discussions about cell therapy and its potential applications for bringing new therapies to patients in need.”\n– Novartis \n“This is a best in class and top summit in the cell therapy area which is an invaluable asset to both industries and academia.”\n– University of Pennsylvania \nJoin us to ensure safe\, consistent and quality cell therapy development with novel\, scalable and automated analytical development assays. \nTo know more about Cell Therapy Analytical Development Summit click here
URL:https://www.pharmajournalist.com/event/cell-therapy-analytical-development-summit/
LOCATION:Revere Hotel Boston Common  200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200115
DTEND;VALUE=DATE:20200117
DTSTAMP:20260515T052243
CREATED:20190802T125805Z
LAST-MODIFIED:20190802T125855Z
UID:21833-1579046400-1579219199@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices 2020
DESCRIPTION:Assessing the regulatory environment and future of PFS design and development \nSMi are pleased to present the 12th Annual Pre-Filled Syringes and Injectable Drug Devices conference in London on 15th and 16th January 2020. \n \nAs Europe’s leading Pre-Filled Syringes conference\, the 2020 event will assess innovations in device engineering and components\, enhancement of human factors\, and optimizing packaging and containment. \nWith the rapid expansion of the PFS market\, the regulatory environment is more importance than ever. This year’s programme will look at the EU MDR\, Article 117 as well as insights into the MDR post-market surveillance requirements; providing a holistic review of the Pre-Filled Syringes industry. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior Pre-Filled Syringes Engineers\, Device Testing Managers\, Heads of Late-Stage Pre-Filled Syringes Development\, Head of Medical Affairs\, Senior Director – Combination Products & Medical Devices\, Global Regulatory Affairs\, Quality Assurance Manager Combination Products \, Senior Pharmaceutical Assessor and many more. \nBENEFITS OF ATTENDING:  \n\nLearn about the technological innovations that are revolutionizing the injectable drug delivery space through novel device design\nDebate how can we prepare for the regulatory impact of Brexit and the EU MDR on devices\nHear industry experts uncovering the latest advancements optimizing drug biologics to improve PFS delivery\nAssess industry case studies exploring how to overcome challenges of extractables and leachables\n\nView the full agenda and speaker line-up online: www.pre-filled-syringes.com/pharmajwl \nPlus\, pre-conference workshop day will be taking place on 14th January in London: \nWorkshop A: A Roadmap to Regulation Quality Management Systems and Technical Standards \nWorkshop B: Testing Requirements of Pre-Filled Syringes led by Horst Koller\, CEO\, HK Packaging Consulting GmbH \nWorkshop C: Extractables and Leachables: Considerations for PFS Platforms \nEARLY-BIRD RATES:  \n\nBOOK BY 30TH SEPTEMBER AND SAVE £400\nBOOK BY 31ST OCTOBER AND SAVE £200\nBOOK BY 29TH NOVEMBER AND SAVE £100\n\nRegistrations can be made on the event website at: www.pre-filled-syringes.com/pharmajwl \nChairs for 2019: \n\nJames Mellman\, Device Manager\, Novartis\nAnil Busimi\, Strategy and Innovation Global Product Manager\, SCHOTT\n\nFeatured speakers: \n\nAbha Raveau-Violette\, Device Manager\, AstraZeneca\nAmanda Matthews\, Senior Director\, Pfizer\nAnil-Kumar Busimi\, Strategy and Innovation\, Senior Global Product Manager\, SCHOTT\nBenjamin Werner\, Scientist\, Boehringer Ingelheim Pharma GmbH & Co. KG\nCedric Gysel\, Healthcare Solutions Manager\, Johnson & Johnson\nCinzia Rotella\, Senior Materials Scientist\, Sanofi\nClemens Guenther\, Director Nonclinical Safety Consumer Care\, Bayer\nColin Roscoe\, Principal Human Factors Scientist\, Teva Pharmaceuticals\nHiroki Hasegawa\, Researcher\, Mitsubishi Gas Chemical Company\, Inc\nJames Mellman\, Device Manager\, Novartis A G\nKewei Yang\, Pharmaceutical Scientist\, Roche\nKhaudeja Bano\, Head of Medical Devices\, Abbott Molecular Inc\nMarion Westwood\, Pharmaceutical Assessor\, Medicines & Healthcare products Regulatory Agency (MHRA)\nMatthew Nicolas\, Investigator\, GlaxoSmithKline\nNicolas Eon\, Senior Global Product Manager\, SCHOTT\nOlaf Lebau\, Design Engineer for Medical Devices and Combination Products\, Boehringer Ingelheim GmbH\nRaphael Nudelman\, Director of Chemical and Computational Toxicology\, Teva Pharmaceuticals\nRemy Vomscheid\, Director\, Devices Development & Technologies\, IPSEN Pharmsciences\nTorsten Kneuss\, Quality Assurance Manager Combination Products\, Bayer Pharma\n\nContact Info: \nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk\nFollow us:  @SMiPharm #PFSSMi
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-2020/
LOCATION:Copthorne Tara Hotel\, Kensington\, Scarsdale Pl\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200120
DTEND;VALUE=DATE:20200122
DTSTAMP:20260515T052243
CREATED:20190823T095903Z
LAST-MODIFIED:20190823T095957Z
UID:22116-1579478400-1579651199@www.pharmajournalist.com
SUMMARY:Disruptive Technologies in Pharma
DESCRIPTION:The conference aims to bring together experts of emerging technologies to discover the opportunities with regards to Artificial intelligence\, Machine Learning\, Internet of Things\, Digital therapeutics\, eHealth and blockchain. The effect of these technologies on the industry will be discussed with the aim to highlight challenges related to the implementation of these new technologies and to discuss how to overcome them. \n \nIndustry case studies will reveal personal experiences and strategies to approaching digitalization\, providing a benchmark for practice and improving understanding of forecasts until 2020. \nTransformations require regulatory adjustments therefore\, the conference will also feature insights into new regulatory guidelines and standards of practice\, with special focus on the new class of drugs called digital therapeutics\, to provide a complete picture of every aspect of the transformation process. \nNetwork and learn from leading professionals such as Vice Presidents\, Directors Managers and Heads of: Emerging/Disruptive Technologies\, Artificial Intelligence\, Machine Learning\, Data Science/Analytics\, Technology\, External and Internal Innovation\, Digital IoT and Bioinformatics \nCHAIRS FOR 2020: \n\nKarl Hess\, Managing Director\, OnDigitalHealth Consulting\n\nFEATURED SPEAKERS INCLUDE: \n\nMark Campbell\, Freelance Regulatory Expert\, former NICE\nVladimir Anisimov\, Principal Data Scientist\, Amgen\nJoseph Dalton\, Global Lead Digital Health Solutions and Medical Outcomes\, Novartis\n\nFor more information and to register\, visit www.disruptivetech-pharma.com/pjwb \nContact Info: \nT: +44 (0) 20 7827 6164\nE: nhoward@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/disruptive-technologies-in-pharma/
LOCATION:HOLIDAY INN KENSINGTON FORUM\, 97 Cromwell Road\, London\, SW7 4DN\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:nhoward@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200120
DTEND;VALUE=DATE:20200122
DTSTAMP:20260515T052243
CREATED:20190906T081615Z
LAST-MODIFIED:20190906T090018Z
UID:22273-1579478400-1579651199@www.pharmajournalist.com
SUMMARY:SMi’s 9th Annual Pharmaceutical Microbiology Conference
DESCRIPTION:SPONSORED BY\nAssociates of Cape Cod\, bioMérieux\, COPAN\, METTLER TOLEDO\, Microgenetics\, Reading Scientific Services Limited\, Veltek Associates \nCHAIRED BY\nJames Drinkwater\, Chairman\, Pharmaceutical and Healthcare Science Society\nOlivier Chancel\, Sterility and Aseptic Practices Expert\, Boehringer Ingelheim \nDiscovering optimised contamination control and the current regulatory landscape \nPharmaceutical Microbiology as an industry is projected to see significant advancements in the next five years. This forecast is largely attributed to rapid microbiology testing\, which has accounted for $3.5 billion last year\, while projected to reach nearly double at $6 billion by 2025\, and an estimated CAGR of 8.3% leading up to 2025. \nAt the very core of pharmaceutical microbiology is the accurate and reliable detection of microorganisms that would otherwise contaminate the pharmaceutical products manufactured. This demand for more rapid methods for detection and identification will be accompanied by equally important areas such as: contamination control strategies and environmental monitoring\, process automation\, and discussing updates to meet regulatory requirements. \nJoin us at SMi’s 9th Annual Pharmaceutical Microbiology Conference to explore novel and developing technologies that tackle the most pressing challenges and push innovation in world of pharmaceutical microbiology. \n Event Hashtag: #SMiPharmaMicroUK \nAt the 9th Annual Pharmaceutical Microbiology Conference\, you will gain insight into: \nFEATURED SPEAKERS INCLUDE: \n\n Luis Meirinhos-Soares\, GMP Inspector\,Infarmed IP\n Jim Polarine\, Senior Technical Service Manager\,STERIS Corporation\n Tim Eaton\, Sterile Manufacturing Specialist\,AstraZeneca\n Pratixa Patel\, Senior Director\,Microbiology and Stability Sciences\, GSK\n Ian Symonds\, Pharmaceutical Consultant\, SDA Pharma\n Michael Song\, Senior Manager\,MedImmune\n Maria Jose Zafra-Domene\, Microbiology QC Team Leader\,MeiraGTx\n Ingo Spreitzer\, Deputy Head Section Microbial Safety\,Paul Ehrlich Institute\n\n KEY HIGHLIGHTS INCLUDE FOR 2020 \n\nDiscuss the regulatory expectations and supportive guidance on bio-contamination control and monitoring in aseptic manufacturing of sterile products fromPHSS\nGain valuable insight from key opinion leaders in a panel discussion on the impact of the Annex 1revisions on pharmaceutical microbiology\nExamine the common myths and urban legends in the pharmaceutical industry related to contamination control from STERIS\nExplore container closure integrity and controls strategies ensuring product sterility from AstraZeneca\nRevisit the role of the Official Medicines Control Laboratories as the GMP back up from Infarmed IP\n\nView the full agenda: www.pharma-microbiology.com/PJwl \nWHO SHOULD ATTEND? \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist Drug Substance External Manufacturer\, Business Development Manager – Testing\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist \n EARLY BIRD-RATES \n\nBOOK BY 30TH SEPTEMBER AND SAVE £400\nBOOK BY 31ST OCTOBER AND SAVE £200\nBOOK BY 29TH NOVEMBER AND SAVE £100
URL:https://www.pharmajournalist.com/event/smis-9th-annual-pharmaceutical-microbiology-conference/
LOCATION:Copthorne Tara Hotel\, London\, UK\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200127
DTEND;VALUE=DATE:20200131
DTSTAMP:20260515T052243
CREATED:20191002T103300Z
LAST-MODIFIED:20191002T104019Z
UID:22677-1580083200-1580428799@www.pharmajournalist.com
SUMMARY:Temperature Control and Logistics
DESCRIPTION:The Temperature Control and Logistics forum remains the industries foremost operational and hands on conference to discuss everything logistics\, supply chain and temperature controlled for the Pharmaceutical Industry. \n \nOur vision for 2020 is to ensure that we remain true to our role in the industry – building a network of world leading expert speakers and facilitators alongside the industries leading solution providers and attendees to address how we can work together to practically advance the industry past the biggest and current hurdles and challenges. We are committed to ensuring that we help every single delegate\, industry partner and expert speaker to achieve their unifying goal: Transforming the industries current capabilities by optimising global logistics and supply chain processes to better serve the patient populations at the heart of the conversation. \nAcross four days of workshops\, keynote presentations\, case studies\, interactive think tank discussions and networking – we will ensure that the industry leaves with the strategies\, solutions and partners to overcome their most pressing operational challenges in order to make industry transformation and – patient care – possible. \nTo learn more about Temperature Control and Logistics visit http://bit.ly/2mRcY8I
URL:https://www.pharmajournalist.com/event/temperature-control-and-logistics/
LOCATION:Crowne Plaza Dusseldorf – Neuss\, Dusseldorf
ORGANIZER;CN="IQPC":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200128
DTEND;VALUE=DATE:20200131
DTSTAMP:20260515T052243
CREATED:20191020T175731Z
LAST-MODIFIED:20191020T175731Z
UID:22984-1580169600-1580428799@www.pharmajournalist.com
SUMMARY:Commercializing Continuous Processing in Pharma (CCP)
DESCRIPTION:The CCP Summit 2020 is the only dedicated community for continuous manufacturing commercialization in Pharma. \nFour years in the drug development world isn’t long\, and the progress made in continuous processing has been an extraordinary. Thanks to the encouragement of the FDA and maturing technology; both pharma and biotech are starting to adopt continuous manufacturing (CM) in a commercial setting. \nOver the last 12 months we have seen major milestones in continuous manufacturing globally – PROSPECT project in the UK\, GSK’s announcement of CM facilities in Singapore\, Merck has filed an NDA under CM approach\, Bill & Melinda Gates Foundation granted $14.3m to Univercells to deploy CM for measles and rubella vaccine continuous manufacturing. \nAt the 4th Annual CCP Summit we will continue to explore scientific and technology advancements that can help eliminate bottlenecks\, and more importantly\, will address the quality\, upfront investment and business rationale behind the ‘switch’. \nThis is the one and only CCP meeting bringing together small molecules and biologics experts under one roof for knowledge and experience exchange! \nJoin us in Boston for the 4th time on Jan 28 – 30\, 2020.  Find out more about the CCP Summit > https://ter.li/9slw1t
URL:https://www.pharmajournalist.com/event/commercializing-continuous-processing-in-pharma-ccp/
LOCATION:The Colonnade\, 120 Huntington Avenue\, Boston\, MA\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200204
DTEND;VALUE=DATE:20200206
DTSTAMP:20260515T052243
CREATED:20191002T082938Z
LAST-MODIFIED:20191002T082938Z
UID:22661-1580774400-1580947199@www.pharmajournalist.com
SUMMARY:Parallel Trade 2020
DESCRIPTION:Exploring the dynamics\, legalities and hurdles in a period of transition for Parallel Trade \nSMi presents Europe’s leading 14th annual Parallel Trade conference\, taking place in London on the 4th-5th of February 2020. As the only B2B parallel trade conference in Europe\, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade. \nThe size of the EU market in pharmaceutical distribution is around €5bn\, and the UK accounts for 22.7% of this figure. The sector has an annual import value of around £1bn\, while the annual export figure approximates £600m. \nThe 2020 event will hold a particular place of significance on shortages of medicines\, current and ongoing challenges posed by Parallel Trading\, potential implications of Brexit and IP exhaustion rights. \nFurthermore\, the FMD (Falsified Medicines Directive) will be coming into effect in February 2020. This conference will give companies affected the perfect opportunity to discuss and consider the impact that the FMD implementation will have on their practices and on the market. \nThe benefits of attending: \nThis conference is a must-attend show for anyone involved in the parallel trade industry within pharmaceuticals and life sciences. Attending the show gives you the chance to interact with and discuss common issues with leaders involved in all the areas of the parallel trade industry. Furthermore\, this provides core information to further strengthen your industry knowledge and approaches. \n\nAssessing the economic impact and dynamics of Parallel Trade\nReviewing how to overcome the challenges and hurdles in Parallel Trade\nUnderstanding the underlying principles of the EU internal market and competition policies\nDiscussing the impact of Parallel trade on patient safety\nWhat’s the impact and consequences of a no deal Brexit on testing and clinical trials?\nImpact on shortages\, availability\, accessibility and innovation\nAssessing current EU legislative instruments and changes in IP framework\nAn update on current illegal trade cases and the Falsified Medicines Directive\n\nEARLY-BIRD RATES: \n\nBOOK BY 31st OCTOBER AND SAVE £400\nBOOK BY 29th NOVEMBER AND SAVE £200\nBOOK BY 13th DECEMBER AND SAVE £100\n\nPlus two pre-conference interactive workshops  \nWorkshop A : Parallel Trade and Brexit… Where are we now?\nTushar Patel\, Principal Consultant\, Key Pharmaceuticals Ltd \nWorkshop B: Understanding IP\, regulatory and competition law issues in pharmaceutical parallel trade\nJohn Schmidt\, Partner\, Antitrust\, Arnold & Porter Kaye Scholer \nAdditional Contact Info: \nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nLinkedIn: @SMi Pharma\nTwitter: @SMiPharm #SMi #SMiParallel
URL:https://www.pharmajournalist.com/event/parallel-trade-2020/
LOCATION:Holiday Inn\, Kensington Forum 97 Cromwell Rd\, Kensington\, London SW7 4DN\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200204
DTEND;VALUE=DATE:20200206
DTSTAMP:20260515T052243
CREATED:20200109T073947Z
LAST-MODIFIED:20200109T073947Z
UID:23578-1580774400-1580947199@www.pharmajournalist.com
SUMMARY:Smartlab Exchange USA
DESCRIPTION:The Smartlab Exchange is an invitation-only meeting bringing together 70 of the most senior lab leaders from across the world\, plus a number of hand-selected solution providers for two days of one-to-one business meetings\, benchmarking\, discussions and networking. \n \nKey themes include: \n✓ Devising a Roadmap to Success for an Agile\, Adaptable\, Digitized Lab\n✓ Harnessing Lab Automation Strategies\n✓ Leverage Big Data Analytics and Informatics\n✓ Augmenting Existing Systems/Processes with Emerging Technologies\n✓ Implementing Methods to Safeguard Data Integrity and Uphold Regulatory Compliance \n96% of our attendees would recommend our event \n“I got more out of one day at Smartlab than a normal day at another conference.” –  R&D IS Program Manager\, Biomerieux \nBelow are some of the 20+ presentations and interactive sessions we have in store: \n\nAbbvie – Transforming The R&D Lab: What It Takes\nIDC – Leveraging AI To Supercharge Data and Analysis Efficiencies In The Connected Lab\nPepsico – Blending Technology\, Process and Digitization To Enable Smart Data-Driven Lab Transformation\nJohnson & Johnson – The Digital Patient & Consumer In Healthcare\n\nCheck out the full agenda here: http://bit.ly/35z1F5m
URL:https://www.pharmajournalist.com/event/smartlab-exchange-usa/
LOCATION:Hilton Fort Lauderdale Marina\, FL\, United States
ORGANIZER;CN="IQPC":MAILTO:info@exchangeevents.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200206
DTEND;VALUE=DATE:20200208
DTSTAMP:20260515T052243
CREATED:20191031T095454Z
LAST-MODIFIED:20191031T104545Z
UID:23112-1580947200-1581119999@www.pharmajournalist.com
SUMMARY:4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference
DESCRIPTION:Since our past editions we dedicated our focus on the latest developments and addressed various applications of CRISPR as a molecular tool\, gene expression\, knock-in\, genomic screening\, along with therapeutic developments through animal modeling. Attended by 100+ genome editing professionals and 20+ gene expert speakers\, the event saw participation of big companies like Casebia Therapeutics\, Genentech\, BMS\, Cellectis \, University of Laval\, University of California\, Center of Advanced Genome Engineering\, Georgia Tech\, Stanford University\, Locana\, Harvard Medical School\, Agility\, Poseida\, Vertex\, Ligandal\, Integrated DNA Technologies\, GE Healthcare\, Cellecta\, Agilent\, Advanced Analytical\, Thermofisher\, Atum\, Synthego\, New England Biolabs\, Aldevron\, Applied Stem Cell and more. \n \nIn 2020\, coming with the 4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference on 6th & 7th February in San Diego\, we are getting ahead by discussing the commercialization and advancements of technology which will outline breakthrough advancements in pre-clinical & clinical therapeutics using genome Editing. The event will also focus on analysis of off target effects\, specificity and aspects of gene and cellular therapies. \nTo learn more about 4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference click here
URL:https://www.pharmajournalist.com/event/4th-edition-marketsandmarkets-genome-editing-gene-therapy-conference/
LOCATION:San Diego\, CA
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:suraj.waghmare@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200206
DTEND;VALUE=DATE:20200208
DTSTAMP:20260515T052243
CREATED:20191031T101817Z
LAST-MODIFIED:20191031T101817Z
UID:23125-1580947200-1581119999@www.pharmajournalist.com
SUMMARY:5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference
DESCRIPTION:The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th – 7th February 2020 in San Diego\, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers\, Precision Medicine and Big Data. Regarding commercialization of biomarkers\, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers. \n \nTo learn more about 5th Annual Biomarker and Companion Diagnostics Conference click here
URL:https://www.pharmajournalist.com/event/5th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-conference/
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:Shardul.oza@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200206
DTEND;VALUE=DATE:20200208
DTSTAMP:20260515T052243
CREATED:20191031T102512Z
LAST-MODIFIED:20191031T104231Z
UID:23129-1580947200-1581119999@www.pharmajournalist.com
SUMMARY:MarketsandMarkets Gen-Next Probiotics and Microbiome Congress
DESCRIPTION:What are the essentials being missed out on? What is the real role of probiotics strains\, prebiotics and symbiotic in influencing a health? How do you standardize microbiome analysis? \nWitness the major breakthroughs of microbiome\, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation\, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis\, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery. \n \nJoin us at Gen-Next Probiotics and Microbiome Congress\, 2020 to network with biotech\, pharma\, academicians and investors to exchange views and observe the most ingenious research and technologies. Understand what’s happening. Witness the amalgamation of study focused on pharmaceutical and medicinal approaches of probiotics and the nutraceutical and consumer approaches along with the role of microbiome in clinical applications and preventative medicine. \nTo learn more about MarketsandMarkets Gen-Next Probiotics and Microbiome Congress click here
URL:https://www.pharmajournalist.com/event/marketsandmarkets-gen-next-probiotics-and-microbiome-congress/
LOCATION:San Diego\, CA
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:suraj.waghmare@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200217
DTEND;VALUE=DATE:20200219
DTSTAMP:20260515T052243
CREATED:20200109T074622Z
LAST-MODIFIED:20200109T074622Z
UID:23582-1581897600-1582070399@www.pharmajournalist.com
SUMMARY:Smartlab Exchange Europe
DESCRIPTION:The Smartlab Exchange is an invitation-only meeting bringing together 70 of the most senior lab leaders from across Europe\, plus a number of hand-selected solution providers for two days of one-to-one business meetings\, benchmarking\, discussions and networking. \n \nKey themes include: \n✓ Devising a Roadmap to Success for an Agile\, Adaptable\, Digitised Lab\n✓ Leveraging Big Data Analytics and Informatics\n✓ Embedding a Culture of Collaboration and Innovation\n✓ Enhancing Visibility Across Existing Systems/Processes and Integrate Emerging Technologies\n✓ Implementing Methods to Safeguard Data Integrity and Uphold Regulatory Compliance \n96% of our attendees would recommend our event \n“I got more out of one day at Smartlab than a normal day at another conference.” –  R&D IS Program Manager\, Biomerieux \nBelow are some of the 20+ presentations and interactive sessions we have in store: \n\nNovartis – Exploring Data Visualisation Software To Increase The Accuracy Of Your Predictions\nRoche – Connecting Your Instruments For Easy Data Access And Analysis Across Your Lab\nJanssen – The Lab Of The Future: Predicting How The Lab Will Develop In the Next 5 Years\nUCB – Developing Your Data Capture Process For Increased Efficiency\n\nCheck out the full agenda here: http://bit.ly/2T75ps7
URL:https://www.pharmajournalist.com/event/smartlab-exchange-europe/
LOCATION:Hotel Palace Berlin\, Germany
ORGANIZER;CN="IQPC":MAILTO:info@exchangeevents.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200218
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T052243
CREATED:20191017T094701Z
LAST-MODIFIED:20191017T094701Z
UID:22911-1581984000-1582243199@www.pharmajournalist.com
SUMMARY:Disposable Solutions for Bio Manufacturing
DESCRIPTION:Now in it’s 12th year\, the 2020 Disposable Solutions for Biomanufacturing Forum is the only global forum that focuses on the use of disposable products and single use systems in biomanufacturing. Our attendees will be guided through their journey and understand how they can run 100% disposable sites and scale their manufacturing capabilities with our newly designed program focused on implementation\, systems management and future technology. \n \nThe three packed days will consist of case studies and interactive sessions to identify new technologies\, determine how to approach automated systems\, transition to continuous processes and learn how to implement best practice in system testing & life cycle management! \nTo learn more about Disposable Solutions for Bio Manufacturing and to register online\, visit http://bit.ly/2Mp6lEs
URL:https://www.pharmajournalist.com/event/disposable-solutions-for-bio-manufacturing/
LOCATION:Leonardo Royal Hotel Berlin Alexanderplatz\, Berlin\, Germany\, Germany
ORGANIZER;CN="IQPC":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200219
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T052243
CREATED:20171019T063951Z
LAST-MODIFIED:20191004T082421Z
UID:3496-1582070400-1582243199@www.pharmajournalist.com
SUMMARY:RNA Therapeutics
DESCRIPTION:SMi Group are pleased to present the 11th Annual RNA Therapeutics Conference and Focus Day in London on February 18th – 20th 2020. \nThe field of RNA therapeutics is rapidly expanding\, and the potential for using RNA drugs for personalised medicines and immunotherapy\, as well as to address genetic\, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come. \n \nThe event will focus on the latest research and developments on delivery system technologies that aim to tackle more difficult targets within the human body. This overarching topic warrants high focus and therefore\, for the first time in the series\, introduce a focus day on Oligonucletide Delivery Systems. The main conference will focus on current developments in the area of mRNA therapeutics in immunotherapy and vaccination. \nNEW FOR 2020: RNA Therapeutics Focus Day – Oligonucleotide Delivery Systems \nIntroducing the only RNA therapeutics conference to hold a full day exploring alternatives to oligonucleotide delivery systems. The global antisense and RNA therapeutics market is expected to expand at a compound annual growth rate (CAGR) of 8.6% between 2019 and 2025\, projected to reach $1.81 billion\, this focus day will assess the growing need for research and development of novel delivery approaches to expand the current delivery methods in today’s market. \nHow will you benefit? \n\nDiscuss the innovations in oligonucleotide delivery systems\nExplore the latest developments in RNA delivery agents and RNA-based therapeutics\nLearn from case studies on clinical developments with leading RNA therapeutics companies and regulatory bodies\nRevisit the challenges for clinical translation of RNA-based therapeutics\nEvaluate the applications of RNA-based drugs for modulation of gene and protein expression\, and genome editing\nGain an expert view on new and upcoming regulatory updates and industry implications\n\nNetwork and learn from leading professionals such as: \nCHAIR FOR 2020 \nHeinrich Haas\, VP RNA Formulation and Drug Delivery\, BioNTech \nFEATURED SPEAKERS INCLUDE: \n\nShalini Andersson\, Chief Scientist New Therapeutic Modalities\, AstraZeneca\nChristian Plank\, CTO\, Ethris\nSteve Pascolo\, Founder and CEO\, Miescher Pharma\nKirsty Wydenbach\, Deputy Unit Manager\, Clinical Trials Unit\, MhRA\nSteven Powell\, CEO\, eTheRNA\nSimon Newman\, CSO\, Nanogenics\nChristiane Niederlaender\, Director\, AMBR Consulting and Formerly\,\nQuality Assessor\, Biologicals\, MhRA\nKlaus Giese\, CEO\, Pantherna Therapeutics\nDavid Blakey\, CSO\, MiNA Therapeutics\nJeffrey Ulmer\, Head Preclinical R&D\, GSK\n\nFor more information and to register\, visit: www.therapeutics-rna.com/pjwb  \nEarly-Bird Rates \nREGISTER BY 31ST OCTOBER TO SAVE £400 \nREGISTER BY 29Th NOVEMBER TO SAVE £200 \nREGISTER BY 13Th DECEMBER TO SAVE £100 \nSocial Media Handles \nFollow us on LinkedIn ‘SMi Pharma’\, Twitter @SMiPharm and use #SMiRNA
URL:https://www.pharmajournalist.com/event/rna-therapeutics/
LOCATION:London\, UK\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:nhoward@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200219
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T052243
CREATED:20191015T105531Z
LAST-MODIFIED:20191015T105531Z
UID:22854-1582070400-1582243199@www.pharmajournalist.com
SUMMARY:SMi’s 4th Annual 3D Cell Culture
DESCRIPTION:CHAIRED BY:\nPhilip Hewitt\, UK and Eurotox Registered Toxicologist\, Global Head of Early Investigative Toxicology\, Merck Healthcare KGaA\nStefan Przyborski\, Professor of Cell Technology\, Durham university \nDevelopment and application of human organs and tissues in vitro\nOver the past few years\, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues\, drug discovery\, predictivity and validation\, and safety and toxicity.\n\nSMi’s 3D Cell Culture Conference will explore advances of organ and lab-on-a-chip\, microphysiological systems\, applications of technology and case studies\, imaging\, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field. \nBioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems. \nFor the first time ever the NEW 3D Bioprinting Focus Day on 18 February 2020 will explore case studies from big pharma\, biotech’s and academia exploring how bioprinting is being used in industry highlighting projects looking at stem cell therapy\, drug screening and extracellular matrix scaffolds. \nEvent Hashtag: #SMi3DCellCulture \nFEATURED SPEAKERS INCLUDE: \n\nLeonard Both\, Senior Quality Assessor\, Biologicals/Biotechnology Unit\, MHRA\nVeronique Barban\, Expert Virology\, Research and Nonclinical Safety Department\, Sanofi Pasteur\nSimone Stahl\, Associate Principal Scientist\, ADME Sciences\, Clinical Pharmacology and Safety Sciences\, AstraZeneca\nWendy Rowan\, Scientific Director\, Novel Human Genetics Research Unit\, GSK\nJason Ekert\, Head of Complex In Vitro Models\, GSK\nSamuel Jackson\, Programme Manager\, Disease Models Efficacy and Safety Pharmacology\, NC3RS\n\nKEY TOPICS FOR 2019 INCLUDE: \n\nLearn from leading pharma companies to benchmark against their applications of 3D technology\nExplore case studies of 3D cell culture\, high throughput screening\, imaging and microphysiological systems in industry\nHear about the latest technology advances allowing 3D bioprinting to revolutionise in vitro models\nDiscuss organ-on-chip technologies and their applications to replace the use of animals in pharmaceutical research\nParticipate in a panel discussion on adopting new technologies for 3D models\n\nView the full agenda: http://www.3d-cellculture.com/PJWL \nWHO SHOULD ATTEND? \nBiotech / Pharma Companies – Team Leader\, Junior Principle investigator\, Cell and Molecular Scientist\, Chief Scientific Officer\, Deputy Director\, Manager\, Founder\, CEO\, Head\, Director\, Programme Manager\, Lab Head\, Toxicologist \nAcademia Professor – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering \nSolution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer \nEARLY BIRD-RATES \n\nREGISTER BY 31ST OCTOBER AND SAVE £400\nREGISTER BY 29TH NOVEMBER AND SAVE £200\nREGISTER BY 13TH DECEMBER AND SAVE £100
URL:https://www.pharmajournalist.com/event/smis-4th-annual-3d-cell-culture/
LOCATION:Copthorne Tara Hotel\, London\, UK\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200224
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T052243
CREATED:20191016T074751Z
LAST-MODIFIED:20191017T085729Z
UID:22867-1582502400-1582847999@www.pharmajournalist.com
SUMMARY:CAR-TCR Europe Summit
DESCRIPTION:With CAR-T therapies on the cusp of achieving global approval\, there are still many bottlenecks that are preventing this from becoming the ‘sell-out’ therapy that the field had hoped for. The CAR-TCR Europe Summit will unravel the technical challenges across translation\, scale and delivery to provide your team with the platform to learn\, collaborate and gain actionable insights to advance your therapy for clinical and commercial success. \nThis focused agenda will delve into the technical bottlenecks encountered in every stage of the CAR-TCR drug development cycle\, providing a comprehensive analysis across 3 tracks including: Translational\, Manufacturing & Clinical \nTo learn more about CAR-TCR Europe Summit and to register online\, visit https://ter.li/9iuqer
URL:https://www.pharmajournalist.com/event/car-tcr-europe-summit/
LOCATION:Novotel London West\, Hammersmith\, London\, W6 8DR
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T052243
CREATED:20191016T073714Z
LAST-MODIFIED:20191017T085556Z
UID:22862-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:3rd Antigen Specific Immune Tolerance Summit
DESCRIPTION:Translating Emerging Antigen Specific Immune Tolerance Approaches for Therapeutic Applications \nAccelerate the progression of ethical and effective antigen specific immunotherapies through the clinic\, optimize the discovery of novel targets and explore novel therapeutic approaches harnessing combination therapies. \n \nBuilding on the success of the 2019 meeting\, the 3rd Antigen Specific Immune Tolerance Summit (ASIT) returns to Boston on February 25-27\, 2020. The meeting will bring together industry representatives from the fields of autoimmunity\, allergy\, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies\, ASIT 2020 is the only antigen specific summit offering thought leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development. \n\nHear from and engage with a world-class speaking faculty made up of 26 industry representatives including Novo Nordisk\, Pfizer\, Merck\, Eli Lilly\, ITN & FDA\nExplore cross learning opportunities from parallel fields tackling immune tolerance and better understand the fundamental mechanisms that lie behind tolerance induction\nEngage with and immerse yourself within a learning journey across three conference days\, tackling all elements of drug development from discovery to clinical development\nGain practical insight from those describing recent clinical trials and determine what mechanisms lie behind successful and unsuccessful clinical trials\nEmploy novel therapeutics in combination with antigen specific immunotherapies and drive the progression of drug development towards the clinic\nTake advantage of intimate networking opportunities with key opinion leaders from large pharma\, biotech and academia through discursive and engaging platforms that spark conversation and debate\n\nTo learn more about 3rd Antigen Specific Immune Tolerance Summit and to register online\, visit https://ter.li/rp07a3
URL:https://www.pharmajournalist.com/event/3rd-antigen-specific-immune-tolerance-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR